<DOC>
	<DOCNO>NCT00800501</DOCNO>
	<brief_summary>This study conduct evaluate safety tolerability drug product sNN0029 , contain growth factor VEGF165 , administer directly one fluid fill cavity brain use implanted catheter implant SynchroMedÂ® II pump . Patients Amyotrophic Lateral Sclerosis enrol .</brief_summary>
	<brief_title>A Safety Tolerability Study Intracerebroventricular Administration sNN0029 Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Vascular endothelial growth factor ( VEGF ) endogenous human protein fundamental development vascular nervous system body . A role VEGF ALS suggest observation animal model disease well observation dysregulation VEGF production patient ALS . NeuroNova intend investigate whether intracerebroventricular administration VEGF165 form drug product sNN029 improve motor function prolong survival patient ALS , first study safety tolerability treatment 3 month evaluate . Assessments include : - Electrocardiograms , vital sign clinical laboratory test - Adverse event withdrawal related adverse event - Possible pathological change brain , spinal cord retina identify magnetic resonance image funduscopy - Possible sign intracranial bleeding loss blood-brain-barrier integrity measurement bilirubin albumin level cerebrospinal fluid collect lumbar cervical puncture - Device performance characterize catheter tip placement ( determined imaging ) infusion accuracy ( pump residual volume ) The secondary objective study : - To explore effect ICV administration sNN0029 time course Amyotrophic Lateral Sclerosis relate parameter include : - Disease activity measure Amyotrophic Lateral Sclerosis Functional Rating Scale - Quality life measure EQ-5D rating scale - To explore level VEGF165 cerebrospinal fluid collect lumbar cervical puncture .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Clinical diagnosis ALS classify definite , probable without additional laboratory evidence , accord revise WFN El Escorial criterion . 2 . Age 18 75 year inclusive . 3 . If patient treat riluzole , must stable dose least 30 day . 4 . Ophthalmological examination screen normal finding regard vascular structure function . 5 . MRI/magnetic resonance angiography ( MRA ) examination brain cervical spinal cord screen finding tumor potential source pathological bleeding , abnormality may interfere assessment safety efficacy would , judgement investigator , represent surgical risk subject . 6 . Values coagulation parameter include platelet count , normalized prothrombin complex ( PKINR ) , activate partial thromboplastin time ( APTT ) within normal range . 7 . Patient medically able undergo surgery require stereotactic implantation catheter infusion pump . 8 . Patient give write verbal information , opportunity ask question study , understands time procedural commitment . 9 . Patient give signed consent ( write ) participate study . In event patient give oral informed consent physically able sign inform consent form ( ICF ) due disease progression , witness may sign ICF patient 's behalf . 1 . Impaired respiratory function judge pose risk patient anaesthesia device implantation . 2 . Hypertension define blood pressure &gt; 160 mmHg systolic &gt; 90 mmHg diastolic . 3 . Diagnosis diabetes mellitus . 4 . Proliferative retinopathy . 5 . Nonproliferative retinopathy moderate severity high . 6 . Concurrent clinically significant dementia determine investigator . 7 . Concurrent clinically significant depression determine investigator . 8 . History structural brain disease ALS , include tumour hyperplasia . 9 . Any disorder precludes surgical procedure ( e.g. , sign sepsis inadequately treated infection ) , alters wind heal ( e.g. , include bleed disorder ) , render chronic ICV delivery device implant medically unsuitable . 10 . Presence risk increase uncontrolled bleeding and/or risk bleed manage optimally . Physicians specifically investigate anatomical factor near implant site ( e.g. , vascular abnormality , neoplasm , abnormality ) , underlie disorder coagulation cascade , platelet function , platelet count ( e.g. , haemophilia , Von Willebrand 's disease , liver disease , medical condition ) , administration antiplatelet anticoagulant medication ( e.g. , aspirin , Plavix , NSAIDs ) pre perioperative period . Any condition drug could place patient increase risk intraoperative postoperative bleeding . 11 . Presence implant shunt drainage CSF implant CNS catheter . 12 . Presence cardiac pacemaker , spinal cord stimulators , implantable programmable intraspinal drug pump , device may interfere interact programmer , without prior approval Medtronic . 13 . Clinically significant abnormality hematology clinical chemistry parameter assess investigator . 14 . Ongoing medical condition accord investigator would interfere conduct assessment study . Examples medical disability ( e.g. , severe degenerative arthritis , compromise nutritional state , peripheral neuropathy ) would interfere assessment safety efficacy investigational product device performance , would compromise ability subject undergo study procedure ( e.g. , MRI ) , give inform consent . 15 . Participation another clinical trial investigational drug device within 3 month prior Screening visit . 16 . For female subject , ongoing pregnancy plan pregnancy period treatment study drug . 17 . Breast feeding period treatment study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>ALS</keyword>
	<keyword>VEGF165</keyword>
	<keyword>Safety</keyword>
	<keyword>Intracerebroventricular</keyword>
	<keyword>Infusion</keyword>
	<keyword>Implantable</keyword>
</DOC>